Mereo BioPharma Reports Results of Alvelestat in P-II (ASTRAEUS) Trial for Alpha-1 Antitrypsin Deficiency-Associated Emphysema
Shots:
- The P-II (ASTRAEUS) study evaluates alvelestat (high/low dose) vs PBO in 99 adults with sev. AATD-related emphysema across 26 sites in the EU, North America & UK
- The results showed significant changes in 3 primary biomarker EPs at high dose, 90% inhibition of blood NE activity in patients with both dose groups @12wk. & reductions in biomarkers Aα-val360 & desmosine at high doses showed a clear impact on the pathogenic pathway of AATD-lung disease
- The additional analyses on other 2EPs & exploratory EPs are expected to complete in H2’22 & the company meets with US FDA & EMA regulators to identify the design of a registrational trial for AATD-LD. The (ATALANTa) trial result is expected in H1’22
Ref: Globenewswire | Image: Mereo BioPharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
